Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ruiz-Irastorza G et al. – Review concludes that hydroxychloroquine (HCQ) should be given to most patients with systemic lupus erythematosus (SLE) during the whole course of the disease, irrespective of its severity, and be continued during pregnancy.

MethodsResults

Exclusive Author Commentary
GUILLERMO RUIZ-IRASTORZA, 06/09/09

This systematic review analysed the available evidence on the use of antimalarials in SLE. Data confirmed them as very effective and safe drugs for the treatment of lupus, with important long-term effects, including a decrease in mortality. More recenta data, published after this review, reinforce the role of antimalarials in preventing thrombosis, also in patients with antiphospholipid antibodies, and in preventing infections. Given the efficacy and safety profile, patients with SLE should be treated long term with hydroxiychloroquine.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address